Oruka Therapeutics, Inc. Payments of Debt Issuance Costs
Oruka Therapeutics, Inc. (ORKA) reported Payments of Debt Issuance Costs of $100.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-08-11
- Oruka Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2024-06-30 was $100.00K.
| Period end | Payments of Debt Issuance Costs 2 month | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 5 month |
|---|---|---|---|
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-11 | $100.00K 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |